The prognosis of MDS/AML in patients with ERCC6L2 germline variants is poor, especially when progression to acute erythroid leukemia is noted, with no known survivors of this AML subtype so far (28). The gene discussed is ERCC6L2; the disease is myelodysplastic syndrome.